Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

Journal of Virology

Volumn 85, Issue 12, 2011, Pages 5804-5813

  Medina Ramirez M ^a,b,e   Sanchez Merino V ^a,b   Sanchez Palomino S ^a,b   Merino Mansilla, A ^a,b   Ferreira, C B ^a,b   Perez I ^a,c   Gonzalez N ^d   Alvarez, A ^d   Alcocer Gonzalez J M ^e   Garcia F ^b,c   Gatell, J M ^b,c   Alcami J ^d   Yuste, E ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; IMMUNOGLOBULIN G; LOPINAVIR; NEUTRALIZING ANTIBODY; RITONAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SCREENING; TREATMENT RESPONSE; VIREMIA; VIRUS ENVELOPE; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADULT; AGED; ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; CROSS REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; RECOMBINATION, GENETIC; VIRAL LOAD; VIREMIA; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79958131570     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02482-10     Document Type: Article

References (89)

1. Ammann, A. J., et al. 1984. B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA 251:1447-1449.
2. Bailey, J. R., et al. 2006. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80:6441-6457.
3. Bailey, J. R., T. M. Williams, R. F. Siliciano, and J. N. Blankson. 2006. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J. Exp. Med. 203:1357-1369.
4. Barbas, C. F., et al. 1992. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U. S. A. 89:9339-9343.
5. Beirnaert, E., et al. 2000. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J. Med. Virol. 62:14-24.
6. Binley, J. M., et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
7. Bonsignori, M., et al. 2009. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J. Immunol. 183:2708-2717.
8. Buchacher, A., et al. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10:359-369.
9. Burrer, R., et al. 2001. Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIVinfected patients. J. Virol. 75:5421-5424.
10. Burrer, R., et al. 2006. Efavirenz in plasma from HIV-infected patients does not directly block reverse transcriptase activity in cell-free assays but inhibits HIV replication in cellular assays. AIDS Res. Hum. Retroviruses 22:865-869.
11. Burton, D. R., et al. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. U. S. A. 88:10134-10137.
12. Burton, D. R., et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
13. Cagigi, A., A. Nilsson, A. De Milito, and F. Chiodi. 2008. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. Vaccine 26:3016-3025.
14. Candotti, D., et al. 1999. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J. Med. Virol. 58:256-263.
15. Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201-208.
16. Carbone, A., et al. 1985. Lymph node immunohistology in intravenous drug abusers with persistent generalized lymphadenopathy. Arch. Pathol. Lab. Med. 109:1007-1012.
17. Cohen Stuart, J. W., et al. 2001. Transient relapses (" blips" ) of plasma HIV RNA levels during HAART are associated with drug resistance. J. Acquir. Immune Defic. Syndr. 28:105-113.
18. Coiras, M., M. R. Lopez-Huertas, M. Perez-Olmeda, and J. Alcami. 2009. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 7:798-812.
19. Crawford, J. M., et al. 1999. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J. Virol. 73:10199-10207.
20. Deeks, S. G., et al. 2006. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J. Virol. 80:6155-6164.
21. De Milito, A., et al. 2004. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 103: 2180-2186.
22. Derdeyn, C. A., et al. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
23. Doria-Rose, N. A., et al. 2010. Breadth of human immunodeficiency virusspecific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636.
24. Doria-Rose, N. A., et al. 2009. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly crossneutralizing antibodies. J. Virol. 83:188-199.
25. Dornadula, G., et al. 1999. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282:1627-1632.
26. Dreyer, K., et al. 1999. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res. Hum. Retroviruses 15:1563-1571.
27. Etemad-Moghadam, B., et al. 1999. Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo. J. Virol. 73:8873-8879.
28. Euler, Z., et al. 2010. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 201:1045-1053.
29. Feikin, D. R., C. Feldman, A. Schuchat, and E. N. Janoff. 2004. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect. Dis. 4:445-455.
30. Fenyo, E. M., et al. 2009. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4:e4505.
31. Furtado, M. R., et al. 1999. Persistence of HIV-1 transcription in peripheralblood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340:1614-1622.
32. Garcia-Perez, J., S. Sanchez-Palomino, M. Perez-Olmeda, B. Fernandez, and J. Alcami. 2007. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J. Med. Virol. 79:127-137.
33. Gonzalez, N., et al. 2010. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J. Antimicrob. Chemother. 65:2493-2501.
34. Graham, B. S. 2002. Clinical trials of HIV vaccines. Annu. Rev. Med. 53:207-221.
35. Gray, E. S., et al. 2009. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype Cinfected blood donors. J. Virol. 83:8925-8937.
36. Havlir, D. V., et al. 2001. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286:171-179.
37. Havlir, D. V., et al. 2003. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J. Virol. 77:11212-11219.
38. Hermankova, M., et al. 2001. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA 286:196-207.
39. Humbert, M., et al. 2007. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Eur. J. Immunol. 37:501-515.
40. Hunt, P. W., et al. 2008. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197:126-133.
41. Kekow, J., P. Kern, H. Schmitz, and W. L. Gross. 1986. Abnormal B-cell response to T-cell-independent polyclonal B-cell activators in homosexuals presenting persistent generalized lymph node enlargement and HTLV-III antibodies. Diagn. Immunol. 4:107-111.
42. Kieffer, T. L., et al. 2004. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 189:1452-1465.
43. Kloosterboer, N., et al. 2005. Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus. Virology 339:70-80.
44. Kroon, F. P., et al. 1998. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 12:F217-F223.
45. Lambotte, O., et al. 2005. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41:1053-1056.
46. Lambotte, O., et al. 2009. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23:897-906.
47. Lane, H. C., et al. 1983. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309:453-458.
48. Learmont, J. C., et al. 1999. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N. Engl. J. Med. 340:1715-1722.
49. Lum, J. J., et al. 2003. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J. Clin. Invest. 111:1547-1554.
50. Mahalanabis, M., et al. 2009. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J. Virol. 83:662-672.
51. Maldarelli, F., et al. 2007. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 3:e46.
52. Mallon, P. W., J. Ray, and D. A. Cooper. 2003. Effect of therapeutic drugmonitoring on outcome in antiretroviral experienced HIV-infected individuals. J. Clin. Virol. 26:223-227.
53. Marzolini, C., et al. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75.
54. Mascola, J. R., et al. 1999. Protection of macaques against pathogenic simian/ human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
55. Mascola, J. R., et al. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173:340-348.
56. Migueles, S. A., et al. 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3:1061-1068.
57. Migueles, S. A., et al. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U. S. A. 97:2709-2714.
58. Moir, S., and A. S. Fauci. 2009. B cells in HIV infection and disease. Nat. Rev. Immunol. 9:235-245.
59. Moir, S., et al. 2008. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J. Infect. Dis. 197:572-579.
60. Mologni, D., et al. 2006. Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. AIDS 20:567-574.
61. Moog, C., H. J. Fleury, I. Pellegrin, A. Kirn, and A. M. Aubertin. 1997. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71:3734-3741.
62. Moore, J. P., et al. 1996. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:427-444.
63. Morris, L., et al. 1998. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J. Exp. Med. 188:233-245.
64. Nettles, R. E., et al. 2005. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 293:817-829.
65. Newman, R. M., et al. 2006. Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc. Natl. Acad. Sci. U. S. A. 103:19134-19139.
66. Overton, E. T., et al. 2005. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin. Infect. Dis. 41:1045-1048.
67. Pahwa, S. G., M. T. Quilop, M. Lange, R. N. Pahwa, and M. H. Grieco. 1984. Defective B-lymphocyte function in homosexual men in relation to the acquired immunodeficiency syndrome. Ann. Intern. Med. 101:757-763.
68. Palmer, S., et al. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 105:3879-3884.
69. Pancera, M., et al. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternaryspecific antibodies that effectively neutralize HIV-1. J. Virol. 84:8098-8110.
70. Perelson, A. S., et al. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191.
71. Pereyra, F., et al. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197:563-571.
72. Persaud, D., et al. 2004. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J. Virol. 78:968-979.
73. Piantadosi, A., et al. 2009. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83:10269-10274.
74. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864.
75. Purtscher, M., et al. 1996. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS 10:587-593.
76. Purtscher, M., et al. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10:1651-1658.
77. Roben, P., et al. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68: 4821-4828.
78. Sather, D. N., et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
79. Scheid, J. F., et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
80. Simek, M. D., et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348.
81. Stiegler, G., et al. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17:1757-1765.
82. Takeuchi, Y., M. O. McClure, and M. Pizzato. 2008. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 82:12585-12588.
83. Titanji, K., et al. 2006. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 108:1580-1587.
84. Tobin, N. H., et al. 2005. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J. Virol. 79:9625-9634.
85. Trkola, A., et al. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
86. Wang, B., et al. 2003. First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. Virology 312:135-150.
87. Wang, Q., et al. 2008. High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors. Microbiol. Immunol. 52:209-215.
88. Wang, S., et al. 2008. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26:1098-1110.
89. Wei, X., et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.